BeiGene, Ltd. (NASDAQ: ONC) — Perfil da empresa, notícias e dados financeiros
BeiGene, Ltd.
ONC BeiGene, Ltd.
Perfil da empresa
BeiGene, Ltd.
BeiGene, Ltd. is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer treatment. The company advances a broad clinical pipeline of small molecule inhibitors, monoclonal antibodies, and bispecific antibodies aimed at addressing hematologic malignancies and solid tumors worldwide. Operating across North America, Europe, Asia-Pacific, and other international regions, the organization conducts research, clinical trials, and commercial operations to improve therapeutic access and outcomes for oncology patients.
Resumo
Public USParticipação acionária
2010Ano de fundação
~12,000Funcionários
Basel, SwitzerlandSede
Carregando mapa...
Presença global
Operações
Produtos e/ou serviços de BeiGene, Ltd.
- Bruton Tyrosine Kinase Inhibitors: Small molecule kinase inhibitors designed to block signals required for B-cell proliferation and survival, indicated for treating chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia globally.
- PD-1 Immune Checkpoint Inhibitors: Humanized IgG4 monoclonal antibodies directed against programmed cell death protein 1, developed to restore anti-tumor immune response in esophageal, gastric, and non-small cell lung cancers across international markets.
- HER2 Bispecific Antibodies: Dual HER2-targeted bispecific antibodies engineered to bind distinct domains of the HER2 receptor, inhibiting cell signaling and mediating tumor cell death in HER2-expressing gastrointestinal and biliary tract cancers.
- Chimeric Degradation Activating Compounds: Targeted protein degradation platform therapies engineered to selectively destroy disease-causing target proteins, including novel next-generation BTK degraders for hematologic malignancies resistant to standard targeted inhibitor treatments.
- Antibody-Drug Conjugates: Monoclonal antibodies chemically conjugated to potent cytotoxic payloads designed to selectively deliver therapeutic agents directly to target tumor cells expressing specific surface antigens across thoracic, gynecological, and gastrointestinal cancers.
- Biopharmaceutical Manufacturing and Supply: Global commercial and clinical-scale production operations encompassing small-molecule chemical synthesis, large-molecule biologics manufacturing, secondary packaging, and supply chain management across specialized facilities in North America, Europe, and Asia.
equipe executiva do BeiGene, Ltd.
- John V. OylerCo-Founder, Executive Chairman & CEO
- Wang LaiPresident and Global Head of Research & Development
- Xiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
- Aaron RosenbergChief Financial Officer
- Chan LeeGeneral Counsel, Senior VP & Corporate Secretary
- Titus B. BallVP & Chief Accounting Officer
- Marcello DamianiChief Technology Officer
- Liza HeapesHead of Investor Relations
- Eleanor DuffSenior VP & Head of Corporate Communications
- Graham HardimanGlobal Head of Human Resources
Últimas notícias sobre a BeiGene, Ltd.
BeOne announces 4 cancer programs for ESMO 2026
United StatesBeOne ZIIHERA trial shows survival improvement
United StatesBeOne wins FDA approval for TEVIMBRA GEA treatment
United StatesBeOne and Revolution Medicines expand oncology partnership
United StatesBeOne Medicines revenue jumps 30% to $1.7 billion
United StatesBeOne Medicines reports positive phase 3 data for Brukinsa plus rituximab in MCL
United States
Principais indicadores financeiros
Resultados divulgados pela BeiGene, Ltd., em USD.
- Cap. de mercado
- 41,6 bi
- Receita (TTM)
- 6,1 bi
- P/L
- 65.5
- LPA (diluído, TTM)
- 5.6
- Dividend yield
- —
- Margem de lucro
- 10.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 5,3 bi | 447,1 mi | 286,9 mi | |
| 3,8 bi | -568,2 mi | -644,8 mi | |
| 2,5 bi | -1,2 bi | -881,7 mi | |
| 1,4 bi | -1,8 bi | -2 bi |